• 9 June 2011
  • News
  • By

Top 26-30

Advanced Enzyme Technologies Advanced Enzyme Technologies (AETL) clocked total sales revenue of 154 crore for FY 2010-11 as compared to 121 crore in 2009-10. The revenue is expected to increase 30 to 35 percent on a year-on-year basis for the next five to eight years. The company operates primarily in four segments, including human health & nutrition, animal nutrition, food processing, and industrial processing. The company is expected to start its European and Chinese subsidiaries soon. More than 50 percent of the company’s sales come from its exports to 53 countries. AETL, which had a overhaul in 2009, developed more than 400 unique enzyme products like luicine amino peptidase (exo-peptidase), candida antarctica lipase b immobilized, a full range of hemicellulase and pectinase enzymes and a full range of grain ethenol enzymes. AETL is also the largest manufacturer of serratiopeptidase, having perfected the art of manufacturing the enzyme over the past 15 years.
Dr CL Rathi

Business: Manufacturing, R&D and marketing of enzymes
Start-up Year: 1989
Address: Sun Magnetica, “A” wing, 5th Floor, LIC Service Road, Louiswadi, Thane (W)- 400 604
Tel: +91-22-41703200
Fax: +91-22-25835159
Website: www.enzyme.com

Revenue: 154 crore*

Lambda Therapeutic Research Lambda Therapeutic Research recorded an estimated sales revenue of 128 crore for 2010-11. The company offers services such as clinical trials implementation, laboratory and data management, information technology support, medical affairs assistance, quality assurance and bio analysis. The CRO has more than 640 clinical beds globally, including a 16-bed phase I unit in Ahmedabad, a 12-bed phase I unit in Toronto, Canada, a six-bed phase I unit in Warsaw, Poland.
The company also has more than 40 LC-MS/MS systems, a CAP/NGSP accredited clinical laboratory, molecular and microbiological laboratory and a low temperature (2-8 °C, -20 °C and -80 °C) controlled storage facility, to store over 4.0 million samples. Lambda Therapeutic Research has additional facilities in Mumbai, India and Erwitte, Germany and has acquired a pharmacovigilance CRO in UK, named Pharm V Solutions.

Ms Bindi Chudgar

Business: Clinical trials implementation, laboratory and data management
Start-up Year: 1999
Address: Near Gujarat High
Court, S. G. Highway, Gota, Ahmedabad-380061

Tel: +91-79-40202020
Fax: +91-79-40202021
Website: www.lambda-cro.com

Revenue: 128 crore*

Concord Biotech Concord Biotech, a R&D-based company that focuses on fermentation and semi-synthetic based products, achieved a total income of 126.17 crore in FY 2010-11 as compared to 111.07 crore in the previous year. It is the largest producer of penicillin-G amidase enzyme, with a market share of 90 percent. It exports this enzyme to a number of companies in China, Europe and the US. Concord also produces and exports lovastatin and tacrolimus and is also starting the production of simvastatin and pravastatin in its new US-FDA approved facility. It now boasts of having one of the largest numbers of bioreactors in India and has setup a lyophilization facility for sterile bulk biopharmaceutical. It also has a manufacturing facility, spread across 28 acres of land, located at Ahmedabad, Gujarat. In FY2010-11, Concord initiated its CRAM business by setting up of its new R&D facility. The company received award for its outstanding contribution to the healthcare sector at Bangalore India Bio 2011.
MD and CEO
Mr Sudhir Vaid
Business: Manufacturing of bulk drugs
Start-up Year: 2002
Address: 302, Sakar-III, Opp: Gujarat High Court, Off ITO Circle, Ashram Road, Ahmedabad-380014
Tel: +91-79-27544998, 27543557
Fax: +91-79-27540802
Website: www.concordbiotech.com

Revenue: 126.17 crore

Ecron Acunova Ecron Acunova is a Bangalore-based CRO with offices across India and operations in 14 European countries. The company recorded revenue worth 125 crore in the FY 2010-11 as compared to 97 crore in FY 2009-10. In January 2011, Ecron Acunova expanded its clinical research center for drug development by 80 beds. The company also announced a joint venture with Jamjuree Innovations(JJI), Thailand and will conduct clinical research in key South East Asian countries under the name, Ecron Acunova Company Limited (EACL).
In April 2011, Ecron Acunova acquired a majority stake in aCROnordic, a Danish CRO specializing in clinical research in Sweden, Finland and Norway. Since its inception five years ago Ecron has conducted over 250 phase I one studies and over 70 late phase studies, which has helped the company reach the third position amongst nearly 100 CROs in India.

Founder & Chairman
Mr DA Prasanna

Business: Clinical research services
Start-up Year: 1986
Address: Manipal Acunova Limited, Mobius Towers, SJR i-Park, EPIP, Whitefield, Bangalore-560066
Tel: +91-80-66915700
Fax: +91-80-66915719
Website: www.ecronacunova.com

Revenue: 125 crore*

Themis Medicare Themis Medicare (TML) achieved a total turnover of 124 crore as against 90 crore for the year ending March 31, 2010.
TML has a plant located in Hyderabad where lovastatin, simvastatin and other fermentation-based actives are produced.
TML boasts of four state-of-the-art manufacturing facilities at three locations, in Vapi (Gujarat), Hyderabad (Andhra Pradesh) and Haridwar (Uttaranchal). The company has a joint venture partnership with Gedeon Richter (Budapest, Hungary), named Richter-Themis Medicare (India) Private Limited and also has signed a long-term business agreement with Schering-Plough Animal Health Corporation, US (SPAH). Although its first breakthrough product was vitamin B12, TML moved on to manufacture several synthetic API and numerous therapeutics.

MD and CEO
Dr Dinesh Patel

Business: Formulations and API of synthetic origin
Start-up Year: 1969
Address: 11/12, Udyog Nagar, S.V.Road, Goregaon (West), Mumbai-400 104
Tel: +91-22-67607080, 28757836
Fax: +91-22-28746621
Website: www.themismedicare.com

Revenue: 124 crore*

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box


GST: Boon or Bane for Healthcare?

Send this article by email